|
|
Talecris Biotherapeutics, Inc. announced today the U.S. Food and Drug Administration (FDA) has granted a Priority Review of Gamunex (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). |
|
|
|
Victory Pharma, Inc. today announced an agreement with Hi-Tech Pharmacal Co., for the exclusive U.S. commercial license rights to NAPRELAN(R). NAPRELAN(R) is a proprietary once-a-day formulation of naproxen sodium indicated for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, tendonitis, bursitis, acute gout, primary dysmenorrhea, and mild to moderate pain. The product will be marketed through Victory's physician-based field sales force deployed throughout the U.S. |
|
|
|
a leading provider of noninvasive cardiac safety services, has announced the award of a 2-year study program worth approximately of $4.3 million dollars. |
|
|
|
In just more than seven years, Endeca went from one customer and modest revenue to 500 customers and $100M-plus in sales. |
|
|
|
Intel Capital, the global investment arm of Intel Corporation, announced today that it invested $10M in Endeca Technologies, Inc., an information access software company. |
|
|
|
Spokane, Wash., 10 January 2008 – Signature Genomic Laboratories’ flagship microarray, the SignatureChip Whole GenomeTM (SignatureChipWGTM), covers a region of the human genome that was recently associated with autism. |
|
|
|
RadPharm, Inc., a leading provider of medical image review services for clinical research, announced the completion of a $10 million Series B financing led by Siemens Venture Capital (“SVC”). Existing investors Ampersand Ventures, Adams Street Partners and Tang Capital Management participated in the financing |
|
|
|
CRI Worldwide, Inc., a leading provider of clinical research services to the global pharmaceutical industry, announced that it has partnered with private equity investors Ampersand Ventures and SV Life Sciences in conjunction with the company’s expansion strategy. |
|
|
|
Magellan Biosciences, an emerging leader in clinical-diagnostics markets worldwide, announced that Steven E. Diamond, PhD, has joined the company as chief scientific officer. |
|
|
|
ChanTest, a leading provider of specialized laboratory testing services for drug discovery and development, announced that it recently completed a private equity financing with Ampersand Ventures. |
|
|
|
Cequent Pharmaceuticals, a pioneer in the development of novel products to deliver RNAi-based treatments to prevent and treat human disease, announced that Novartis Option Fund has invested in the company, completing Cequent's Series A round of financing. |
|
|
|
Endeca, an enterprise information access software company, today announced that it achieved record revenues on 92 percent year-over-year revenue growth in the first quarter. |
|
|
|
ChanTest, Inc. (Cleveland, Ohio, USA) today announced its appointment of Cambridge BioScience as its new European Distributor. |
|
|
|
Ortho Organizers, Inc., a leading manufacturer of orthodontic products, announced today that it has launched the Ancor Pro OrthodonticAnchorage System. |
|
|
|
Talecris Biotherapeutics, Inc. announced today that the first patient has been enrolled in its Phase I/Phase II clinical trial investigating the ability of Plasmin to treat acute Peripheral Arterial Occlusion (aPAO). |
|
|
|
Victory Pharma, Inc. today announced an agreement with Hi-Tech Pharmacal Co., for the exclusive U.S. commercial license rights to NAPRELAN(R). |
|
|
|
Victory Pharma, Inc. announced today the U.S. Food and Drug Administration (FDA) completed its review for the company's Investigational New Drug (IND) application to evaluate MGX-006, a unique formulation of a currently marketed agent with indications for various nausea and vomiting conditions. |
|
|
|
|
|
|
|
|
|
|
|
|
